Brief Reports Open Access
Copyright ©The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2005; 11(31): 4875-4878
Published online Aug 21, 2005. doi: 10.3748/wjg.v11.i31.4875
Ursodeoxycholic acid and superoxide anion
Predrag Ljubuncic, Omar Abu-Salach, Arieh Bomzon, Department of Pharmacology, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Author contributions: All authors contributed equally to the work.
Correspondence to: Arieh Bomzon, Department of Pharmacology, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron Street, Po Box 9649, Haifa 31096, Israel. bomzon@tx.technion.ac.il
Telephone: +972-4-8295259 Fax: +972-4-8524978
Received: December 24, 2004
Revised: January 10, 2005
Accepted: January 13, 2005
Published online: August 21, 2005

Abstract

AIM: To investigate the ability of ursodeoxycholic acid (UDCA) to scavenge superoxide anion (O2-).

METHODS: We assessed the ability of UDCA to scavenge (O2-) generated by xanthine-xanthine oxidase (X-XO) in a cell-free system and its effect on the rate of O2--induced ascorbic acid (AA) oxidation in hepatic post-mitochondrial supernatants.

RESULTS: UDCA at a concentration as high as 1 mmol/L did not impair the ability of the X-XO system to generate O2-, but could scavenge O2- at concentrations of 0.5 and 1 mmol/L, and decrease the rate of AA oxidation at a concentration of 100 µmol/L.

CONCLUSION: UDCA can scavenge O2-, an action that may be beneficial to patients with primary biliary cirrhosis.

Key Words: Ursodeoxycholic acid; Superoxide anion; Antioxidant



INTRODUCTION

Ursodeoxycholic acid (UDCA) is a naturally occurring tertiary dihydroxy hydrophilic bile acid used with considerable success in the treatment of primary biliary cirrhosis (PBC)[1-5]. Traditional mechanisms whereby UDCA is beneficial to the diseased liver center on its ability to block the deleterious actions and encourage the choleresis of toxic bile acids[6]. We have reported that UDCA has antioxidant properties. This finding is based on our observation that 100 μmol/L UDCA could prevent oxidative activation of cultured macrophages by the pro-oxidant hydrophobic bile acid, deoxycholic acid[7]. In a follow-up in vivo study, we demonstrated that the therapeutic dose of 15 mg/kg UDCA administered for 24 d, suppresses the augmented extent of lipid peroxidation in the diseased liver of bile duct-ligated (BDL) rats, a widely used animal model of cholestatic liver disease[8]. Accordingly, we proposed the antioxidant action of UDCA could contribute to its beneficial effect in patients with PBC[7,8]. This proposal was recently confirmed by Serviddio and his colleagues who reported UDCA administered for 28 d minimized oxidative damage in the diseased liver of BDL rats[9]. Other studies have established that UDCA can augment the biosynthesis of glutathione (GSH) and thiol-containing proteins in hepatocytes[10,11] and could scavenge the hydroxyl radical (OH-) in a cell-free system[12]. Collectively, these findings have contributed to our current awareness that UDCA is a binary antioxidant possessing direct and indirect antioxidant properties.

Superoxide anion (O2) is a reactive oxygen species (ROS) generated in microsomal and mitochondrial electron transport systems when oxygen is reduced by a single electron. It can also be generated by numerous oxidative enzymes including cytosolic xanthine oxidase (XO) during oxidation of xanthine (X) to uric acid. The generation of O2- is important, because its biotransformation can lead to formation of hydrogen peroxide through the activity of superoxide dismutase, generation of OH radical in the presence of transition metals such as Fe2+ or formation of the reactive peroxynitrite radical by interacting with nitric oxide. Any intervention reducing or preventing excessive generation of O2 would result in decreased production of reactive oxygen and nitroxy species thereby lowering the extent of oxidative stress.

Mitsuyoshi et al[10], reported that UDCA increases hepatocyte levels of GSH and thiol-containing proteins. In this experiment, they spectrophotometrically measured the rate of oxidation of ascorbic acid (AA) by O2- and reported that the difference of absorbance before and after the addition of XO was lower in UDCA-treated hepatocytes than in controls. Since bile acids are enzyme inhibitors[13,14], the difference in absorbance may be due to UDCA inhibiting the ability of the X-XO system to generate O2-. Because Mitsuyoshi et al, did not assess the effect of UDCA on the generation of O2- by X-XO system in their investigation, we evaluated the ability of UDCA to scavenge O2- generated in the X-XO system and its effect on the activity of XO.

MATERIALS AND METHODS
Chemicals and reagents

All chemicals and reagents of the highest purity were purchased from the Sigma Chemical Co. (St. Louis, MO, USA), except for UDCA that was purchased as its sodium salt from Megapharm Ltd, the Israeli agent of Calbiochem-Novabiochem Corporation.

Preparation of hepatic post-mitochondrial supernatants

The livers were harvested from healthy rats used as “healthy untreated controls’ in institute-approved animal-based investigations. The harvested livers were washed in normal ice-cold saline, weighed and then cut into small pieces using scissors before their homogenization in 100 mmol/L ice-cold phosphate buffer, pH 7.4 at 4 °C with a Potter-Elvehjem glass homogenizer. The crude liver homogenates were centrifuged (1 000 r/min×10 min) at 4 °C. The resultant supernatants were then centrifuged at 10 000 g×10 min at 4 °C to pellet mitochondria and the supernatant was collected. The protein content in the supernatants was determined by the method of Lowry et al[15].

Analytical procedures

Ability of UDCA to scavenge superoxide anion Using the xanthine-xanthine oxidase (X-XO) reaction to generate O2-[16], we evaluated the ability of 0.01-1 mmol/L UDCA to scavenge O2- by the nitroblue tetrazolium (NBT) reduction assay[17]. The reaction mixture contained 100 μmol/L Na2EDTA, 40 μmol/L X, and 40 μmol/L NBT in 10 mmol/L phosphate buffer pH 7.4. The reaction was started by adding 10 mU/mL XO and its rate was continuously monitored spectrophotometrically at A560 nm for 15 min at 25 °C in the absence and presence of different concentrations of UDCA. The specificity of the reaction was confirmed by 300 mU/mL superoxide dismutase. The ability of UDCA to scavenge O2-, as expressed as percentage of inhibition of NBT reduction in UDCA-present samples compared to NBT reduction in UDCA-absent samples. The experiment was repeated between 9 and 11 times at each UDCA concentration.

Effect of UDCA on activity of xanthine oxidase

Compounds interacting with XO could affect the kinetics of reaction of oxidation of xanthine to uric acid[18]. Accordingly, we assessed the effect of 0.01-1 mmol/L UDCA on XO activity by spectrophotometrically monitoring the rate of uric acid formation at A295 nm for 3 min at 25 °C in the absence and presence of UDCA[19]. The rate of uric acid formation was compared in the absence and presence of UDCA. The specificity of the reaction was confirmed by 100 μg/mL allopurinol. The experiment was repeated nine times at each UDCA concentration.

Effect of UDCA on hepatic antioxidant capacity

The effect of 100 μmol/L UDCA on hepatic antioxidant capacity was determined by monitoring the rate of oxidation of AA by the O2- generated by the X-XO according to the original method of Nishikimi[20] with modifications described by Mitsuyoshi et al[10]. Liver supernatants were incubated for 120 min at 37 °C in shaking water bath in the absence and presence of 100 μmol/L UDCA. Upon completion of the incubation, the change in the rate of oxidation of AA was monitored in a quartz cuvette containing 1 mL reaction mixture. The post-mitochondrial liver supernatant contained 100 μmol/L X, 100 μmol/L EDTA, 22 μg/mL catalase, 100 μmol/L AA and 0.1 mol/L phosphate buffer pH 7.4. The assay reaction was commenced by adding 10 mU/mL XO. The reaction was monitored spectrophotometrically at A250 nm for 10 min at 25 °C. The differences in absorbance between UDCA-absent and UDCA-added samples were compared. The results were expressed as the reaction rate of AA oxidation (△ absorbance/mg protein). The experiment was repeated thrice.

Experimental design and statistical analysis

The data were analyzed using a two-tailed t-test. The sample size for each experiment was determined by power analysis arbitrarily set between 80-90% in order to detect the effect at the 5% significance level using StatmateTM version 1 (GraphPad Software Inc., San Diego, CA, USA). All figures were prepared using PrismTM version 3.02 (GraphPad Software Inc., San Diego, CA, USA). All data were expressed as mean±SD.

RESULTS
Ability of UDCA to scavenge O2- and effect of UDCA on activity of xanthine oxidase

Figure 1A summarizes the experiments to establish whether UDCA could scavenge O2- using the NBT reduction assay. UDCA (10 µmol/L and 100 µmol/L) had no effect on NBT reduction (Figures 1 A1 and A2). Higher concentrations of UDCA (500 µmol/L and 1 mmol/L) slowed the rate of NBT reduction by 11% and 16% respectively (Figure 1A3 and A4). In order to eliminate the possibility that UDCA suppressed the rate of conversion of X to uric acid to account for this O2- scavenging ability, we also measured the effects of the identical concentrations of UDCA on XO activity. None of the UDCA concentrations affected the rate of formation of uric acid (Figure 1B). Overall, these experiments demonstrated UDCA could scavenge O2- without affecting the activity of XO.

Figure 1
Figure 1 Ability of UDCA to scavenge O2 (A) and effect of UDCA on activity of xanthine oxidase (B) in a cell-free system. 1P<0.02, bP<0.01 vs control.
Effect of UDCA on rate of oxidation of ascorbic acid

UDCA (100 µmol/L) significantly (P<0.002) decreased the rate of AA oxidation (Figure 2).

Figure 2
Figure 2 Effect of 100 mmol/L UDCA on rate of oxidation of AA by O2 generated by X-XO in post-mitochondrial hepatic supernatants. 1P<0.002 vs control.
DISCUSSION

The aim of the present study was to assess the ability of UDCA to scavenge O2- and its effects on the activity of XO in a cell-free system and post-mitochondrial supernatants prepared from rat livers. In the cell-free experiments, we used UDCA concentrations not greater than 1 mmol/L in order to avoid the problems when extrapolating data to cell-containing systems in which millimolar concentrations of bile acids solubilize membranes to form micellar poly-aggregates (critical micellar concentration)[21-23]. On the other hand, we used 100 μmol/L UDCA in the experiments conducted in post-mitochondrial supernatants because this is the concentration used by Mitsuyoshi et al[10], and that found in the plasma of patients treated with UDCA[24]. Using NBT reduction in the cell-free X-XO system to evaluate the ability of UDCA to scavenge O2-, we found UDCA could scavenge O2 at concentrations of 0.5 and 1 mmol/L, respectively. Given the knowledge that bile acids can inhibit enzyme activity[13,14], we checked the possibility that suppression of the activity of XO accounted for ability of UDCA to scavenge O2-. We found that UDCA at concentrations as high as 1 mmol/L did not inhibit the rate of conversion of X to uric acid. After establishing that UDCA could not impair the ability of the X-XO system to generate O2-, we then evaluated the effect of 100 μmol/L UDCA on the rate of O2--induced AA oxidation in hepatic post-mitochondrial supernatants. We found that UDCA decreased the rate of AA oxidation. This result agrees with that of Mitsuyoshi et al[10].

Is the scavenging of O2- by UDCA therapeutically relevant? Free-radical-induced peroxidation of phospholipids has been implicated in the pathogenesis of the formation of cholesterol gallstones[25-27]. In addition, Liu and Hu demonstrated that O2- can attack the bilirubin molecule to generate cytotoxic bilirubin radicals. ROS can also be generated in bile because hydrophobic bile acids are pro-oxidants[28,29]. It was reported that the concentration of UDCA in bile may reach as high as 29 mmol/L in individuals given 750 mg UDCA daily for 2-3 wk[30]. In our experiments, UDCA scavenged O2- at the concentrations of 0.5 and 1 mmol/L suggesting that the ability of UDCA to scavenge O2- may be beneficial in bile.

Lapenna et al[12], reported that UDCA is an efficient OH- scavenger. We have confirmed their finding and established the second order rate constant (k2) for the reaction of UDCA with OH in the D-ribose oxidation assay exceeded the rate constants of other OH radical scavengers, such as mannitol or dimethylsulfoxide (Ljubuncic, Abu-Salach and Bomzon, unpublished results). In conclusion, UDCA is a direct scavenger of superoxide anion and hydroxyl radicals.

Footnotes

Science Editor Wang XL and Guo SY Language Editor Elsevier HK

References
1.  Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;1:834-836.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 398]  [Cited by in F6Publishing: 385]  [Article Influence: 10.4]  [Reference Citation Analysis (0)]
2.  Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn. 1990;25:774-780.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149-1156.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 279]  [Cited by in F6Publishing: 241]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
4.  Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284-1290.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Leuschner U, Güldütuna S, Imhof M, Hübner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol. 1994;21:624-633.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 35]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
6.  Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525-531.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 484]  [Cited by in F6Publishing: 463]  [Article Influence: 21.0]  [Reference Citation Analysis (0)]
7.  Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut. 1996;39:475-478.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 75]  [Cited by in F6Publishing: 87]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
8.  Ljubuncic P, Tanne Z, Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci. 2000;45:1921-1928.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 32]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
9.  Serviddio G, Pereda J, Pallardó FV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Viña J, Sastre J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology. 2004;39:711-720.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 111]  [Cited by in F6Publishing: 103]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
10.  Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263:537-542.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 109]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
11.  Rodríguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut. 2002;50:701-706.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 21]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
12.  Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol. 2002;64:1661-1667.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 73]  [Cited by in F6Publishing: 75]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
13.  Parkinson TM, Olson JA. Inhibitory effects of bile acids on adenosine tryphosphatase, oxygen consumption, and the transport and diffusion of water soluble substances in the small intestine of the rat. Life Sci. 1964;3:107-112.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 38]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
14.  Krähenbühl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology. 1992;15:1160-1166.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 61]  [Cited by in F6Publishing: 63]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
15.  Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968;243:5753-5760.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593-597.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1324]  [Cited by in F6Publishing: 1317]  [Article Influence: 37.6]  [Reference Citation Analysis (0)]
18.  Fridovich I. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J Biol Chem. 1970;245:4053-4057.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Marcocci L, Suzuki YJ, Tsuchiya M, Packer L. Antioxidant activity of nitecapone and its analog OR-1246: effect of structural modification on antioxidant action. Methods Enzymol. 1994;234:526-541.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 10]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
20.  Nishikimi M. Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem Biophys Res Commun. 1975;63:463-468.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 422]  [Cited by in F6Publishing: 374]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
21.  Heaton KW. The importance of keeping bile salts in their place. Gut. 1969;10:857-863.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 29]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
22.  Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989;30:719-730.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Roda A, Minutello A, Angellotti MA, Fini A. Bile acid structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC. J Lipid Res. 1990;31:1433-1443.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E, Bircher J, Fölsch U, Klaus J, Endele R. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology. 1990;12:492-497.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 101]  [Cited by in F6Publishing: 100]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
25.  Lichtenberg D, Ragimova S, Peled Y, Halpern Z. Phospholipid peroxidation as a factor in gallstone pathogenesis. FEBS Lett. 1988;228:179-181.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 8]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
26.  Eder MI, Miquel JF, Jongst D, Paumgartner G, von Ritter C. Reactive oxygen metabolites promote cholesterol crystal formation in model bile: role of lipid peroxidation. Free Radic Biol Med. 1996;20:743-749.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 30]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
27.  Leo MA, Aleynik SI, Siegel JH, Kasmin FE, Aleynik MK, Lieber CS. F2-isoprostane and 4-hydroxynonenal excretion in human bile of patients with biliary tract and pancreatic disorders. Am J Gastroenterol. 1997;92:2069-2072.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Sokol RJ, Devereaux M, Khandwala R, O'Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology. 1993;17:869-881.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 137]  [Cited by in F6Publishing: 129]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
29.  Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology. 1995;109:1249-1256.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 208]  [Cited by in F6Publishing: 214]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
30.  Fischer S, Neubrand M, Paumgartner G. Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum and urine. Eur J Clin Invest. 1993;23:28-36.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 27]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]